Cargando…

Integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects

Background: Topical application of tacrolimus (FK506) was effective in treating atopic dermatitis (AD); however, the therapeutic efficiency is hampered by its poor penetration into the skin and local side effects of transient irritation symptoms with a burning sensation, a feeling of warmth or heat....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yixuan, Cao, Sisi, Yu, Kaiyue, Yang, Fengdie, Yu, Xiuming, Zhai, Yuanhao, Wu, Chuanbin, Xu, Yuehong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679700/
https://www.ncbi.nlm.nih.gov/pubmed/31440050
http://dx.doi.org/10.2147/IJN.S212260
_version_ 1783441391180840960
author Wang, Yixuan
Cao, Sisi
Yu, Kaiyue
Yang, Fengdie
Yu, Xiuming
Zhai, Yuanhao
Wu, Chuanbin
Xu, Yuehong
author_facet Wang, Yixuan
Cao, Sisi
Yu, Kaiyue
Yang, Fengdie
Yu, Xiuming
Zhai, Yuanhao
Wu, Chuanbin
Xu, Yuehong
author_sort Wang, Yixuan
collection PubMed
description Background: Topical application of tacrolimus (FK506) was effective in treating atopic dermatitis (AD); however, the therapeutic efficiency is hampered by its poor penetration into the skin and local side effects of transient irritation symptoms with a burning sensation, a feeling of warmth or heat. Menthol and camphor have been widely used in topical compound formulations for adjunctive pharmacotherapy for antipruritics and analgesics owing to their cool nature, and both present skin penetration enhancing effects. Moreover, they can form a liquid eutectic oil to solubilize hydrophobic drugs. Purpose: Taking advantages of menthol/camphor eutectic (MCE), this work aims to integrate FK506 into MCE to construct a microemulsion system, i.e., FK506 MCE ME, which simultaneously enhances the percutaneous delivery and treatment efficacy, while reduces the side effects of FK506. Methods: The formulation of FK506 MCE ME was optimized and characterized. Different formulations containing FK506 were topically administered to treat 1–chloro–2, 4–dinitrobenzene (DNCB)-induced murine AD. Results: MCE solubilized FK506. FK506 in MCE ME penetrated skin in vitro more than in the commercial ointment, and MCE predominantly exerted the enhancing effects in MCE ME. FK506 MCE ME or FK506 MCE ME gel had greater effects on clinical symptoms, histological analysis, and IgE than did commercial FK506. The anti-pruritic and down-regulation of substance P effects of MCE ME vehicle mitigated the side effects of FK506 application. Conclusion: MCE ME presented the excellent properties of simultaneously enhancing the percutaneous delivery and treatment efficacy, while reducing the side effects of FK506 for AD. Therefore, MCE ME is a promising nanoscale system for FK506 to effectively treating AD with low irritation and high medication adherence. Chemical compounds studied in this article: Tacrolimus (PubChem CID: 445643); menthol (PubChem CID: 1254); camphor (PubChem CID: 2537)
format Online
Article
Text
id pubmed-6679700
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66797002019-08-22 Integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects Wang, Yixuan Cao, Sisi Yu, Kaiyue Yang, Fengdie Yu, Xiuming Zhai, Yuanhao Wu, Chuanbin Xu, Yuehong Int J Nanomedicine Original Research Background: Topical application of tacrolimus (FK506) was effective in treating atopic dermatitis (AD); however, the therapeutic efficiency is hampered by its poor penetration into the skin and local side effects of transient irritation symptoms with a burning sensation, a feeling of warmth or heat. Menthol and camphor have been widely used in topical compound formulations for adjunctive pharmacotherapy for antipruritics and analgesics owing to their cool nature, and both present skin penetration enhancing effects. Moreover, they can form a liquid eutectic oil to solubilize hydrophobic drugs. Purpose: Taking advantages of menthol/camphor eutectic (MCE), this work aims to integrate FK506 into MCE to construct a microemulsion system, i.e., FK506 MCE ME, which simultaneously enhances the percutaneous delivery and treatment efficacy, while reduces the side effects of FK506. Methods: The formulation of FK506 MCE ME was optimized and characterized. Different formulations containing FK506 were topically administered to treat 1–chloro–2, 4–dinitrobenzene (DNCB)-induced murine AD. Results: MCE solubilized FK506. FK506 in MCE ME penetrated skin in vitro more than in the commercial ointment, and MCE predominantly exerted the enhancing effects in MCE ME. FK506 MCE ME or FK506 MCE ME gel had greater effects on clinical symptoms, histological analysis, and IgE than did commercial FK506. The anti-pruritic and down-regulation of substance P effects of MCE ME vehicle mitigated the side effects of FK506 application. Conclusion: MCE ME presented the excellent properties of simultaneously enhancing the percutaneous delivery and treatment efficacy, while reducing the side effects of FK506 for AD. Therefore, MCE ME is a promising nanoscale system for FK506 to effectively treating AD with low irritation and high medication adherence. Chemical compounds studied in this article: Tacrolimus (PubChem CID: 445643); menthol (PubChem CID: 1254); camphor (PubChem CID: 2537) Dove 2019-07-30 /pmc/articles/PMC6679700/ /pubmed/31440050 http://dx.doi.org/10.2147/IJN.S212260 Text en © 2019 Wang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wang, Yixuan
Cao, Sisi
Yu, Kaiyue
Yang, Fengdie
Yu, Xiuming
Zhai, Yuanhao
Wu, Chuanbin
Xu, Yuehong
Integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects
title Integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects
title_full Integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects
title_fullStr Integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects
title_full_unstemmed Integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects
title_short Integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects
title_sort integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679700/
https://www.ncbi.nlm.nih.gov/pubmed/31440050
http://dx.doi.org/10.2147/IJN.S212260
work_keys_str_mv AT wangyixuan integratingtacrolimusintoeutecticoilbasedmicroemulsionforatopicdermatitissimultaneouslyenhancingpercutaneousdeliveryandtreatmentefficacywithrelievingsideeffects
AT caosisi integratingtacrolimusintoeutecticoilbasedmicroemulsionforatopicdermatitissimultaneouslyenhancingpercutaneousdeliveryandtreatmentefficacywithrelievingsideeffects
AT yukaiyue integratingtacrolimusintoeutecticoilbasedmicroemulsionforatopicdermatitissimultaneouslyenhancingpercutaneousdeliveryandtreatmentefficacywithrelievingsideeffects
AT yangfengdie integratingtacrolimusintoeutecticoilbasedmicroemulsionforatopicdermatitissimultaneouslyenhancingpercutaneousdeliveryandtreatmentefficacywithrelievingsideeffects
AT yuxiuming integratingtacrolimusintoeutecticoilbasedmicroemulsionforatopicdermatitissimultaneouslyenhancingpercutaneousdeliveryandtreatmentefficacywithrelievingsideeffects
AT zhaiyuanhao integratingtacrolimusintoeutecticoilbasedmicroemulsionforatopicdermatitissimultaneouslyenhancingpercutaneousdeliveryandtreatmentefficacywithrelievingsideeffects
AT wuchuanbin integratingtacrolimusintoeutecticoilbasedmicroemulsionforatopicdermatitissimultaneouslyenhancingpercutaneousdeliveryandtreatmentefficacywithrelievingsideeffects
AT xuyuehong integratingtacrolimusintoeutecticoilbasedmicroemulsionforatopicdermatitissimultaneouslyenhancingpercutaneousdeliveryandtreatmentefficacywithrelievingsideeffects